Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 12/20 | 0.42 |
| ▸ | GPR6 | P46095 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15738137 | 0.90 | NPC1 (0.45) | NPC1RAB9AGRM5GPR6UCHL1 | |
| SCHEMBL168541 | 0.86 | GRM5 (0.42) | NPC1RAB9AGRM5UCHL1MAPK14 | |
| SCHEMBL164792 | 0.86 | NPC1 (0.48) | NPC1RAB9AGRM5GPR6UCHL1 | |
| SCHEMBL15738855 | 0.86 | NPC1 (0.48) | NPC1RAB9AGRM5GPR6HRH3 | |
| SCHEMBL15737218 | 0.84 | HRH3 (0.35) | NPC1RAB9AGRM5GPR6HRH3 | |
| SCHEMBL12474148 | 0.84 | NPC1 (0.46) | NPC1RAB9AGRM5GPR6HRH3 | |
| SCHEMBL166685 | 0.82 | NPC1 (0.37) | NPC1RAB9AGRM5GPR6HRH3 | |
| SCHEMBL175170 | 0.82 | NPC1 (0.39) | NPC1RAB9AGRM5GPR6HRH3 | |
| SCHEMBL166290 | 0.82 | NPC1 (0.43) | NPC1RAB9AGRM5GPR6HRH3 | |
| Cadaverine Tartrate SCHEMBL165886 | 0.81 | NPC1 (0.46) | NPC1RAB9AGRM5GPR6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611444-B1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-14 | — | — | EP | claimed |
| US-8912179-B2 | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-12-16 | — | — | US | claimed |
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-29 | — | — | US | claimed |
| EP-2611444-B1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| US-8912179-B2 | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-12-16 | — | — | US | disclosed |
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2611444-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029070-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | HRH3, HRH4, HRH1 | NPC1 1118/4885RAB9A 1485/4885GRM5 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.